CMS Suggests Noncoverage of Boston Sci Wingspan, Except In Clinical Trials
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's Wingspan intracranial stent would not be covered by Medicare except during FDA-cleared clinical trials, according to a 1CMS proposed rule issued Aug. 9
You may also be interested in...
Boston Sci’s Wingspan Gets Limited Nat’l Coverage; Broad HDE Policy Will Wait
Medicare will nationally cover intracranial stenting and angioplasty only in the controlled setting of FDA-cleared clinical trials, CMS says
Boston Sci’s Wingspan Gets Limited Nat’l Coverage; Broad HDE Policy Will Wait
Medicare will nationally cover intracranial stenting and angioplasty only in the controlled setting of FDA-cleared clinical trials, CMS says
Wingspan Coverage Policy Has Broad Implications For Humanitarian Devices
CMS' proposed coverage decision for Boston Scientific's Wingspan intracranial stent has stakeholders on edge about the precedent the agency could set in its first national decision for a humanitarian-use device